HLPMF yields 4.51% · PFE yields 6.13%● Live data
📍 HLPMF pulled ahead of the other in Year 1
Combined, HLPMF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HLPMF + PFE for your $10,000?
HELLENiQ ENERGY Holdings S.A., together with its subsidiaries, operates in the energy sector primarily in Greece, South Eastern Europe, and the East Mediterranean. It operates through the Refining, Marketing, Exploration and Production of Hydrocarbons, Petro-chemicals, Gas and Power, and Other segments. The company engages in the refining, supply, and trading of petroleum products; marketing of fuels; production and trading of petrochemicals/chemicals; exploration and production of oil and gas; and generation and trading of power. It is also involved in the production, distribution, and trading of renewable energy sources; provision of financing and other financial services; retail trade of liquid fuels and LPG; operation of tankers; exploration and production of hydrocarbons; trade, distribution, and storage of oil products; and construction and operation of crude oil pipelines. In addition, the company engages in the owning of vessels; production and marketing of lubricants, polypropylene, and solvents; trading of imported plastics and chemicals; production and trade of BOPP films; construction and operation of fuel storage facilities; and provision of treasury, consulting, and engineering services. It operates a network of 1,682 service stations, 15 fuel storage and distribution facilities, 24 aircraft refueling stations in the Greek airports, 2 LPG bottling plants, and 1 lubricant production and packing site in Greece. The company was formerly known as Hellenic Petroleum Holdings Societe Anonyme and changed its name to HELLENiQ ENERGY Holdings S.A. in September 2022. HELLENiQ ENERGY Holdings S.A. was founded in 1998 and is headquartered in Marousi, Greece.
Full HLPMF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.